Good morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and relaxing, because that predictable routine of meetings, deadlines the like has, of course, returned. This did not take too long, did it? Well, what can you do except to join us for a lovely cup or three of stimulation. Our flavor today is, once again, coconut, for those tracking this sort of thing. This means, though, that it is time to get cracking. So here you go: a few tidbits to get you started. Have a smashing day and please do keep in touch. We enjoy your postcards …

Novartis (NVS) agreed to pay $8.7 billion for AveXis (AVXS), a gene therapy company, as the big drug maker looks to deals to refresh its drug development pipeline. The move comes shortly after Novartis chief executive Vasant Narasimhan agreed to cash out of its consumer health joint venture with GlaxoSmithKline. The deal is a bet that at least one promising drug that AveXis is developing for therapies aimed at spinal muscular atrophy will translate into a blockbuster and, as STAT notes, is the second foray by Novartis into gene therapy this year.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy